Products Press Releases Partnering Careers Contact

Featured Post

SLENYTO® (melatonin extended-release tablets) is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS).

August 11, 2026

March 11, 2022

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

January 5, 2022

Shield Therapeutics and KYE Pharmaceuticals Inc Announce Exclusive licence agreement for development and commercialisation of Accrufer®

June 3, 2021

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

May 4, 2021

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)

January 5, 2021

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets)

October 28, 2020

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada